Home » Stocks » CYDY

CytoDyn, Inc. (CYDY)

Stock Price: $2.91 USD -1.14 (-28.15%)
Updated Mar 8, 2021 3:59 PM EST - Market closed
Market Cap 1.82B
Revenue (ttm) n/a
Net Income (ttm) -159.18M
Shares Out 577.95M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE 10.81
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $2.91
Previous Close $4.05
Change ($) -1.14
Change (%) -28.15%
Day's Open 2.90
Day's Range 2.70 - 3.28
Day's Volume 21,344,379
52-Week Range 0.81 - 10.01

News

Hide News
  • All
  • Videos
  • Press Releases
Proactive Investors - 12 hours ago

12:48pm: Dow, Nasdaq headed in opposite directions The Dow was up 605 points, 1.9%, at 32,101 at midday, and the S&P 500 picked up 36 points, almost 1%, to 3,878 points. The Nasdaq, meanwhile,...

Other stocks mentioned: ALPP, BETRF, DIS, EPWCF, EQTRF, GTBAF, KULR, NPEZF, ORGS, TECXF
Proactive Investors - 16 hours ago

CytoDyn Inc (OTCQB:CYDY) said a Phase III trial of its leronlimab treatment, known as Vyrologix, for severe-to-critical patients with coronavirus (COVID-19) has demonstrated continued safety, ...

GlobeNewsWire - 19 hours ago

These trial results are currently being prepared to be submitted for publication

GlobeNewsWire - 19 hours ago

U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA

GlobeNewsWire - 19 hours ago

VANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14...

GlobeNewsWire - 2 days ago

U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA

GlobeNewsWire - 3 days ago

VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14...

GlobeNewsWire - 3 days ago

VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14...

GlobeNewsWire - 5 days ago

VANCOUVER, Washington, March 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14...

InvestorPlace - 2 weeks ago

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

Other stocks mentioned: AIM, CDMO, FLGT, HGEN, JAGX, PRTC
Proactive Investors - 2 weeks ago

CytoDyn Inc (OTCQB:CYDY) announced Monday that study results have been unblinded from the CD12 trial of its drug Vyrologix (leronlimab or PRO-140) in coronavirus (COVID-19) patients, and the c...

GlobeNewsWire - 2 weeks ago

CytoDyn expects to release CD12 data and complete discussions with various regulatory agencies within 2 to 3 weeks

GlobeNewsWire - 1 month ago

CytoDyn will dedicate at least 200,000 vials (100,000 doses) of leronlimab from its inventory to Chiral Pharma Corp. for potential sales in the Philippines

Seeking Alpha - 1 month ago

CytoDyn and Humanigen are running high-visibility trials focused on ameliorating COVID-19 acute inflammation. Acute inflammation plays a major role in the hospitalizations and deaths of patien...

Other stocks mentioned: HGEN
GlobeNewsWire - 2 months ago

Correction to inclusion/exclusion criteria for eIND authorization

GlobeNewsWire - 2 months ago

Manuscript entitled: “Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab,” by Nicholas J. Agresti, M.D.

GlobeNewsWire - 2 months ago

The agency also provided specific guidance for inclusion/exclusion criteria for patients seeking leronlimab under eIND authorization

GlobeNewsWire - 2 months ago

VANCOUVER, Washington, Dec. 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140...

GlobeNewsWire - 2 months ago

The agency will also consider eINDs for patients in other hospitals who qualify for inclusion criteria similar to CD12

GlobeNewsWire - 2 months ago

FDA's decision will enable CytoDyn to respond to ongoing requests for leronlimab until Phase 3 trial data is unblinded

Zacks Investment Research - 2 months ago

CytoDyn (CYDY) completes full enrollment for its phase III registrational study of Vyrologix for the treatment of patients with severe-to-critical COVID-19.

Seeking Alpha - 2 months ago

Overview of CytoDyn Inc. Focus on large molecule (biologic) Leronlimab, patient need, recent clinical trials, and competition for HIV indication.

GlobeNewsWire - 2 months ago

CytoDyn is simultaneously finalizing an EUA application with the Philippine FDA with patient data from CD10 and recent eINDs for severe-to-critical patients

GlobeNewsWire - 3 months ago

VANCOUVER, Washington, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140...

Zacks Investment Research - 3 months ago

CytoDyn (CYDY) enrolls first patient in the phase II study evaluating leronlimab for the treatment of nonalcoholic steatohepatitis.

GlobeNewsWire - 3 months ago

Preclinical results demonstrated leronlimab effectively inhibited fatty liver development

GlobeNewsWire - 3 months ago

Vyrologix™ (leronlimab) has successfully replicated the CCR5 deficient phenotype in a pre-clinical animal study, and will now initiate HIV cure-focused clinical studies in collaboration with ...

GlobeNewsWire - 3 months ago

Concurrently, CytoDyn is w orking d iligently with the FDA to initiate its Phase 2 COVID-19 Long Hauler T rial , with m ore than 100 volu n teers wanting to enroll

GlobeNewsWire - 3 months ago

Rapid Enrollment Expected , As Many People Have Already Volunteered

GlobeNewsWire - 3 months ago

       Vyrologix is the proprietary name for leronli ma b

GlobeNewsWire - 3 months ago

VANCOUVER, Washington, Nov. 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...

GlobeNewsWire - 3 months ago

VANCOUVER, Washington, Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $CYDY #CYDY--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CytoDyn Inc.

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)-- #CYDY--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether CytoDyn, Inc. (“...

GlobeNewsWire - 4 months ago

VANCOUVER, Washington, Nov. 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...

GlobeNewsWire - 4 months ago

VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...

GlobeNewsWire - 4 months ago

VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...

GlobeNewsWire - 4 months ago

Dr. Rahman's 18 years of pharmaceutical industry experience is highlighted by 16 successful BLA/NDAs and sBLAs

GlobeNewsWire - 4 months ago

DSMC recommend s CytoDyn continue the study as planned, with the protocol defined sample size and power to achieve the primary endpoint

GlobeNewsWire - 4 months ago

VANCOUVER, Washington, Oct. 19, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...

GlobeNewsWire - 4 months ago

VANCOUVER, Washington, Oct. 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...

GlobeNewsWire - 4 months ago

VANCOUVER, Washington, Oct. 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...

GlobeNewsWire - 5 months ago

VANCOUVER, Washington, Sept. 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR...

GlobeNewsWire - 5 months ago

VANCOUVER, Washington, Sept. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR...

GlobeNewsWire - 5 months ago

VANCOUVER, Washington, Sept. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR...

Seeking Alpha - 5 months ago

Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles

Other stocks mentioned: BMY, GILD, GNBT, IMMU, INO, MESO, MRNA, NVAX, PFE, SRNE
Seeking Alpha - 5 months ago

CytoDyn: Bulls Continue To Get Torpedoed But The Thesis Remain Afloat

GlobeNewsWire - 5 months ago

VANCOUVER, Washington, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR...

GlobeNewsWire - 6 months ago

U.S. FDA schedules Type A meeting with CytoDyn to discuss BLA filing for HIV   

GlobeNewsWire - 6 months ago

Leading experts in the fields of HIV, Oncology, Rheumatology, and NASH join together to facilitate the best approaches to utilize multiple opportunities for leronlimab

About CYDY

CytoDyn, a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement wi... [Read more...]

Industry
Biotechnology
Stock Exchange
OTCMKTS
Ticker Symbol
CYDY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for CytoDyn is 4.00, which is an increase of 37.46% from the latest price.

Price Target
$4.00
(37.46% upside)